Artificial intelligence (AI) is transforming the practice of medicine. It opens unprecedented new opportunities for diagnostics, drug development and precision healthcare.
The University of Oxford and King Abdulaziz University jointly launch an innovative programme, known as the Centre of Artificial Intelligence for Precision Medicines (CAIPM).
The overarching aim of the programme is to accelerate medicines discovery using AI technologies, for diseases with unmet need, including rare diseases and cardio-metabolic diseases. Our vision is to become internationally recognized beacon for AI-driven drug discovery, that can deliver real world change for human diseases.
Our research programmes will be ambitious, cross-disciplinary, and high-impact.
The Centre will unite leading scientists from both universities, and utilize core research strengths in AI, machine learning and data analytics.
Through therapeutic development, technology exchange, joint publications and building startups, the Centre will be an international partnership at the forefront of innovations in AI and precision medicine.